{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-08-27",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 2
    }
  },
  "results": [
    {
      "discontinued_date": "12/01/2025",
      "update_type": "New",
      "initial_posting_date": "12/01/2025",
      "package_ndc": "59212-111-14",
      "generic_name": "Nilutamide Tablet",
      "contact_info": "847-283-7921",
      "related_info": "Product to expire in March 2026; Discontinuation of the manufacture of the drug",
      "update_date": "12/01/2025",
      "therapeutic_category": [
        "Oncology"
      ],
      "dosage_form": "Tablet",
      "presentation": "Nilandron, Tablet, 150 mg (NDC 59212-111-14)",
      "company_name": "Advanz Pharma (US) Corp.",
      "status": "To Be Discontinued"
    }
  ]
}